scholarly journals Targeted production of reactive oxygen species in mitochondria to overcome cancer drug resistance

2018 ◽  
Vol 9 (1) ◽  
Author(s):  
Hai Wang ◽  
Zan Gao ◽  
Xuanyou Liu ◽  
Pranay Agarwal ◽  
Shuting Zhao ◽  
...  
2021 ◽  
Author(s):  
Tasaduq Hussain Wani ◽  
Goutam Chowdhury ◽  
Anindita Chakrabarty

The anti-cancer drug YM155's primary mode of action is generation of reactive oxygen species, while survivin suppression and DNA damage are secondary effects.


2021 ◽  
Vol 22 (24) ◽  
pp. 13514
Author(s):  
Jin-Hee Kwon ◽  
Na-Gyeong Lee ◽  
A-Ram Kang ◽  
Jie-Young Song ◽  
Sang-Gu Hwang ◽  
...  

β-apopicropodophyllin (APP), a derivative of podophyllotoxin (PPT), has been identified as a potential anti-cancer drug. This study tested whether APP acts as an anti-cancer drug and can sensitize colorectal cancer (CRC) cells to radiation treatment. APP exerted an anti-cancer effect against the CRC cell lines HCT116, DLD-1, SW480, and COLO320DM, with IC50 values of 7.88 nM, 8.22 nM, 9.84 nM, and 7.757 nM, respectively, for the induction of DNA damage. Clonogenic and cell counting assays indicated that the combined treatment of APP and γ-ionizing radiation (IR) showed greater retardation of cell growth than either treatment alone, suggesting that APP sensitized CRC cells to IR. Annexin V–propidium iodide (PI) assays and immunoblot analysis showed that the combined treatment of APP and IR increased apoptosis in CRC cells compared with either APP or IR alone. Results obtained from the xenograft experiments also indicated that the combination of APP and IR enhanced apoptosis in the in vivo animal model. Apoptosis induction by the combined treatment of APP and IR resulted from reactive oxygen species (ROS). Inhibition of ROS by N-acetylcysteine (NAC) restored cell viability and decreased the induction of apoptosis by APP and IR in CRC cells. Taken together, these results indicate that a combined treatment of APP and IR might promote apoptosis by inducing ROS in CRC cells.


2013 ◽  
Vol 57 (9) ◽  
pp. 1638-1648 ◽  
Author(s):  
Giuliana D. Noratto ◽  
Indira Jutooru ◽  
Stephen Safe ◽  
Gabriela Angel-Morales ◽  
Susanne U. Mertens-Talcott

2007 ◽  
Vol 359 (2) ◽  
pp. 304-310 ◽  
Author(s):  
In Tae Hwang ◽  
Young Min Chung ◽  
Jung Jin Kim ◽  
Jin Sil Chung ◽  
Byung Soo Kim ◽  
...  

2019 ◽  
Vol 41 (7) ◽  
pp. 961-971 ◽  
Author(s):  
Yuna Niu ◽  
Xue Yang ◽  
Yifei Chen ◽  
Xinyue Jin ◽  
Li Li ◽  
...  

Abstract Ecotropic viral integration site 1 (EVI1) is an oncogenic transcription factor, which is abnormally expressed in myeloid leukemia and other several solid cancers. It is associated with short survival as well as anticancer drug resistance. Autophagy is a protective mechanism that promotes cancer cell growth and survival under stressed conditions including clinical drug treatment. Here evidences are provided that EVI1 induces autophagy and mediated drug resistance in myeloid leukemia cells. Both knockdown using RNAi and pharmacological inhibition of autophagy significantly increase sensitivity to cytotoxic drug treatment in EVI1high cells. Mechanistic studies revealed that EVI1 regulated autophagy by directly binding to autophagy-related gene autophagy related 7 (ATG7) promoter and transcriptionally upregulating its expression. Notably, ATG7 expression was positively correlated with EVI1 in bone marrow mononuclear cells from myeloid leukemia patients. Acute myeloid leukemia patients with high level of EVI1 are associated with unfavorable overall survival, which was aggravated by simultaneous high expression of ATG7 in these patients. Furthermore, ChIP and firefly luciferase reporter assay identified an EVI1-binding site at 227 upstream promoter region of ATG7 which regulated its transcription. In addition, enforced expression of EVI1 also increased intracellular reactive oxygen species and ATG7 mRNA levels as well as autophagy activity, whereas the increase was attenuated after treatment with reactive oxygen species scavenger, suggesting the involvement of reactive oxygen species in EVI1-induced autophagy. These findings demonstrate that EVI protects myeloid leukemia cell from anticancer drug treatment by inducing autophagy through dual control of ATG7. These results might present a new therapeutic approach for improving treatment outcome in myelogenous leukemia with EVI1high.


Sign in / Sign up

Export Citation Format

Share Document